SYGNIS AG Signs Supply Agreement with US Biological for the Lightning-Link Antibody Labelling Technology
News Nov 28, 2017
Heikki Lanckriet, CEO and CSO of SYGNIS AG, commented: “We are delighted that US Biological has chosen Lighting-Link® as its preferred method for antibody labelling. The technology has clear advantages in terms of simplicity and reproducibility, which will ultimately benefit US Biological’s customers by increasing the range of products available.”
US Biological is a global manufacturer and distributor of bioreagents, offering world-wide distribution of over 1,000,000 antibodies, biochemicals, biologicals, cell culture media, research kits and molecular biology bioreagents. The Company will use Lightning-Link as its preferred antibody conjugation technology to expand its existing catalogue by enabling the production of additional labels, and allowing the company to address a broader range of markets. In addition to core labels for the Lightning-Link range (horseradish peroxidase, alkaline phosphatase, and Fluorescein), the agreement gives US Biological the option to access the full range of Innova-branded products, including Europium and gold nanoparticles.
Lightning-Link antibody and protein labelling technology provides the world’s fastest, easiest to use and most efficient method of antibody conjugation, offering highly stable antibody and protein conjugation with only 30 seconds hands-on time, and no separation steps. Lightning-Link can make a range of assays easier, quicker and more sensitive, and contribute to reduced project costs. Lightning-Link technology offers consistently high quality and easy scalability, with excellent batch-to-batch reproducibility, leading to reduced manufacturing costs.
Tailor-made Protein Fights Several Species of BacteriaNews
As resistance to existing antibiotics increases, new approaches to serious bacterial infections are needed. Now researchers have investigated one such alternative.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE
Blood Sample Detection Method for Multiple Sclerosis DiscoveredNews
A method for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research team. The process will avoid the invasive, painful process of collecting fluid from the brain and spineREAD MORE